Digestive Enzyme Compositions for E. coli Eradication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate in effectively preventing and treating E. coli infections, particularly antibiotic-resistant and virulent strains, and in reducing E. coli contamination on surfaces, as they fail to provide comprehensive solutions for both human and environmental disinfection.
Innovation Solution
The use of pharmaceutical compositions comprising digestive enzymes, such as pancreatic or plant-, fungal-, or microorganism-derived enzymes, which can be administered orally or topically to treat E. coli infections in humans and animals, and as disinfectants, sanitizers, or detergents to reduce E. coli on surfaces, degrading bacterial cell walls and membranes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotic methods are used to treat E. coli infections, then some bacterial growth is inhibited, but antibiotic-resistant and virulent strains remain ineffective against current treatments
Solution Approach 1:
The patent changes the chemical parameter from conventional antibiotics to digestive enzymes (proteases, amylases, lipases), fundamentally altering the mechanism of action to achieve effectiveness against antibiotic-resistant E. coli strains through enzymatic degradation of bacterial cell walls and toxins
Solution Approach 2:
The invention combines multiple types of digestive enzymes (proteases, amylases, lipases) into a composite pharmaceutical composition, creating synergistic effects that provide broad-spectrum activity against various E. coli strains including resistant and virulent types
2Productivity
If current disinfection methods are applied to surfaces, then some E. coli is reduced, but comprehensive eradication and prevention of spread are inadequate
Solution Approach 1:
The digestive enzyme composition serves multiple functions simultaneously: it acts as an antibacterial agent, a disinfectant, a toxin neutralizer, and a preventive measure, providing comprehensive E. coli control across different applications including surface treatment and pharmaceutical use
3Ease of manufacture
If single-function treatments are used, then specific E. coli strains are targeted, but comprehensive solutions for both human treatment and environmental disinfection are not provided
Solution Approach 1:
The same digestive enzyme-based composition is formulated for dual purposes: as a pharmaceutical composition for treating E. coli infections in humans and animals, and as a disinfectant/sanitizer for environmental surfaces, eliminating the need for separate treatment and disinfection products
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The digestive enzyme compositions demonstrate bacteriocidal and bacteriostatic activity against E. coli, effectively treating infections, reducing surface contamination, and preventing the spread of E. coli, while being suitable for various administration forms and applications.
Implementation Method 1
pharmaceutical compositions comprising digestive enzymes, such as pancreatic or plant-, fungal-, or microorganism-derived enzymes
Implementation Method 2
enzymes...degrading bacterial cell walls and membranes
Data Source
AI summary
Compositions and methods for treating or preventing E. coli infections are provided. The compositions can be formulated as pharmaceutical compositions or as disinfectants, sanitizers, detergents or antiseptics, and can be used to eradicate or reduce E. coli populations and thereby treat or prevent infection by E. coli. The compositions include one or more digestive enzymes, e.g., one or more protease, lipases, and amylases. Methods of use of the compositions are also provided.